Noaber
VC Fund
Lunteren, The Netherlands
Noaber is a VC fund in Lunteren focused on Health Care and Medical. Noaber Ventures invests in initiatives that bring social transformations using information technology.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Noaber invests in
Stages Noaber invests in
Countries Noaber invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $423k–$6.3M
- Series A
- $3M–$20M
Investment Focus
Industry
- Health Care 14 (70%)
- Medical 7 (35%)
- Fitness 3 (15%)
- Hospital 3 (15%)
- Software 3 (15%)
Stage
- Seed 7 (35%)
- Series A 3 (15%)
- Funding Round 2 (10%)
- Pre-Seed 1 (5%)
- Series B 1 (5%)
Country
- The Netherlands 6 (30%)
- Israel 2 (10%)
- Germany 2 (10%)
- Sweden 1 (5%)
- Finland 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Matthijs Blokhuis
Managing Director & Chief Executive Officer
|
Managing Director & Chief Executive Officer | Total investments: 3 | Find email | |
|
Mineke Baan-Pas
Co-Founder & Board Member
|
Co-Founder & Board Member | Total investments: 0 | Find email | |
|
Paul Baan
Co-Founder & Strategic Advisor
|
Co-Founder & Strategic Advisor | Total investments: 0 | Find email | |
Tim Dolman
Investment Manager
|
Investment Manager | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mirantus Health
|
Mirantus is building a distributed healthcare provider to improve access to care for underserved patients. Through healthcare services (Mirantus Care) and cloud-solutions (Mirantus OS), Mirantus empowers doctors to efficiently treat patients who were difficult to reach before. This improves healthcare access for patients, allows physicians to earnmore, while saving payors billions in downstream costs. Mirantus is on a mission to get every specialist physician in Europe to participate in distributed healthcare, to improve healthcare access for 100M+ underserved patients. | $6.3M / Seed / Nov 20, 2025 | |
Plasmacure
|
Plasmacure is a medical device to cure advanced wounds | $7M / Series A / Jul 07, 2025 | |
Alba Health
|
Alba Health is a wellness product. It is not intended to diagnose or treat disease, and it is not a substitute for medical advice. | $2.5M / Seed / May 27, 2025 | |
|
Alba Health
|
Alba Health is a wellness product. It is not intended to diagnose or treat disease, and it is not a substitute for medical advice. | $2.1M / Pre-Seed / Jun 21, 2023 | |
Newsenselab (M-sense)
|
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app. | Seed / Dec 20, 2021 | |
|
Newsenselab (M-sense)
|
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app. | $422.9K / Seed / Dec 20, 2021 | |
Elsa
|
Elsa is a platform for patient driven research for better drugs, health and prevention. Elsa lets patients become their own personal researchers by providing them with a better understanding around how lifestyle factors may affect their disease activity measurements for chronic disease. To support them from a scientific perspective, Elsa gives themaccess to data on their specific disease (initially we work with rheumatoid arthritis) through the Riskminder foundation and scientific studies at Karolinska Institutet. | $4.4M / Seed / Nov 05, 2021 | |
Sweetch
|
Sweetch is the first behavioral science company to leverage AI & EI (emotional intelligence) through its digital therapeutics solutions. Its hyper-personalized precision engagement platform enables health ecosystem players to build continuous relationships and engage with every individual patient, at scale. | $20M / Series A / Jul 19, 2021 | |
|
Elsa
|
Elsa is a platform for patient driven research for better drugs, health and prevention. Elsa lets patients become their own personal researchers by providing them with a better understanding around how lifestyle factors may affect their disease activity measurements for chronic disease. To support them from a scientific perspective, Elsa gives themaccess to data on their specific disease (initially we work with rheumatoid arthritis) through the Riskminder foundation and scientific studies at Karolinska Institutet. | $2.1M / Seed / Jan 19, 2020 | |
|
Newsenselab (M-sense)
|
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app. | $1.3M / Seed / Dec 03, 2019 | |
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Noaber invest in?
Noaber invests primarily in Health Care, Medical and Fitness startups, most often at Seed and Series A stage. Most of the 20 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Noaber's check size?
Noaber typically joins rounds of $423k–$6.3M at Seed and $3M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Noaber participates in.
How do I contact Noaber?
Public channels for Noaber include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Noaber?
The team at Noaber includes Matthijs Blokhuis (Managing Director & Chief Executive Officer), Mineke Baan-Pas (Co-Founder & Board Member) and Paul Baan (Co-Founder & Strategic Advisor). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
